Home LiteratureArticle Details
PMID: 27890174 Published · ppublish English Journal Article Review Research Support, Non-U.S. Gov't

Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.

Rheumatic diseases clinics of North America ·Vol. 43 ·No. 1 ·2017-00-00 ·Pages 65-78

Cappelli LC, Shah AA, Bingham CO

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.

Keywords
Arthritis Immune checkpoint inhibitors Immune-related adverse events Malignancy Sicca syndrome
MeSH Terms
Arthritis/chemically induced,immunology Autoimmune Diseases/complications,immunology Disease Progression Humans Immunotherapy/adverse effects Myositis/chemically induced,immunology Neoplasms/complications,drug therapy Rheumatology Sjogren's Syndrome/chemically induced,immunology Vasculitis/chemically induced,immunology
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Cappelli Laura C
Division of Rheumatology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Suite 1.B1, Baltimore, MD, USA. Electronic address: lcappel1@jhmi.edu.
Shah Ami A
Division of Rheumatology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Suite 1.B1, Baltimore, MD, USA.
Bingham Clifton O
Division of Rheumatology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Suite 1.B1, Baltimore, MD, USA.
Conflict of Interest

Dr. Bingham has served as a consultant for Bristol-Myers-Squibb.

References (52)
52 references, click to expand
  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2015 Oct 22;373(17):1627-39 PMID: 26412456
  2. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.
    J Immunother. 2015 Jan;38(1):37-9 PMID: 25415286
  3. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
    Lancet Oncol. 2010 Feb;11(2):155-64 PMID: 20004617
  4. Anti-CTLA4 antibody-induced lupus nephritis.
    N Engl J Med. 2009 Jul 9;361(2):211-2 PMID: 19587352
  5. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
    Clin Cancer Res. 2015 Feb 15;21(4):712-20 PMID: 25524312
  6. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
    Sci Transl Med. 2014 Apr 2;6(230):230ra45 PMID: 24695685
  7. Immune checkpoint blockade: a common denominator approach to cancer therapy.
    Cancer Cell. 2015 Apr 13;27(4):450-61 PMID: 25858804
  8. Ipilimumab in a patient with known Crohn's disease: to give or not to give?
    J Crohns Colitis. 2014 Dec;8(12 ):1742 PMID: 25154682
  9. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
    Clin Ther. 2015 Apr 1;37(4):755-63 PMID: 25746738
  10. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Am J Health Syst Pharm. 2016 Feb 15;73(4):193-201 PMID: 26843495
  11. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.
    J Immunother Cancer. 2015 May 19;3:19 PMID: 25992290
  12. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    J Clin Oncol. 2010 Jul 1;28(19):3167-75 PMID: 20516446
  13. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
    J Immunother. 2013 Sep;36(7):382-9 PMID: 23924790
  14. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
    N Engl J Med. 2006 Feb 16;354(7):709-18 PMID: 16481638
  15. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
    Dig Dis Sci. 2016 Jul;61(7):2132-9 PMID: 26846115
  16. Management of immune-related adverse events and kinetics of response with ipilimumab.
    J Clin Oncol. 2012 Jul 20;30(21):2691-7 PMID: 22614989
  17. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    AJR Am J Roentgenol. 2011 Dec;197(6):W992-W1000 PMID: 22109345
  18. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
    N Engl J Med. 2016 Jun 30;374(26):2542-52 PMID: 27093365
  19. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.
    Arthritis Rheumatol. 2014 Mar;66(3):768-9 PMID: 24574239
  20. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
    Invest New Drugs. 2011 Jun;29(3):489-98 PMID: 20082117
  21. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
    N Engl J Med. 2015 May 21;372(21):2006-17 PMID: 25891304
  22. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  23. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    J Clin Oncol. 2015 May 1;33(13):1430-7 PMID: 25452452
  24. Review: cancer-induced autoimmunity in the rheumatic diseases.
    Arthritis Rheumatol. 2015 Feb;67(2):317-26 PMID: 25371098
  25. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    N Engl J Med. 2015 Nov 5;373(19):1803-13 PMID: 26406148
  26. The blockade of immune checkpoints in cancer immunotherapy.
    Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PMID: 22437870
  27. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    J Rheumatol. 2007 Jun;34(6):1401-14 PMID: 17552067
  28. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  29. Malignancy as a comorbidity in rheumatic diseases.
    Rheumatology (Oxford). 2013 Jan;52(1):5-14 PMID: 22829694
  30. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
    Arthritis Rheum. 2006 May;54(5):1608-18 PMID: 16646004
  31. Nivolumab: targeting PD-1 to bolster antitumor immunity.
    Future Oncol. 2015;11(9):1307-26 PMID: 25798726
  32. Case of respiratory discomfort due to myositis after administration of nivolumab.
    J Dermatol. 2015 Oct;42(10 ):1008-9 PMID: 26104017
  33. IL-2: the first effective immunotherapy for human cancer.
    J Immunol. 2014 Jun 15;192(12):5451-8 PMID: 24907378
  34. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2015 Jun 25;372(26):2521-32 PMID: 25891173
  35. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
    Dig Dis Sci. 2009 Nov;54(11):2538-40 PMID: 19104936
  36. PTR-MS Characterization of VOCs Associated with Commercial Aromatic Bakery Yeasts of Wine and Beer Origin.
    Molecules. 2016 Apr 12;21(4):483 PMID: 27077836
  37. Managing immune checkpoint-blocking antibody side effects.
    Am Soc Clin Oncol Educ Book. 2015 ;:76-83 PMID: 25993145
  38. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
    Arthritis Rheum. 2010 Sep;62(9):2787-95 PMID: 20506513
  39. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
    Ann Oncol. 2015 Dec;26(12):2375-91 PMID: 26371282
  40. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    JAMA Dermatol. 2015 Feb;151(2):195-9 PMID: 25321335
  41. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
    Cancer Immunol Res. 2016 Mar;4(3):175-8 PMID: 26822024
  42. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    N Engl J Med. 2015 Jul 9;373(2):123-35 PMID: 26028407
  43. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2014 Jun;15(7):700-12 PMID: 24831977
  44. Management of toxicities of immune checkpoint inhibitors.
    Cancer Treat Rev. 2016 Mar;44:51-60 PMID: 26874776
  45. Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment.
    Arthritis Rheumatol. 2016 Feb;68(2):556-7 PMID: 26314277
  46. Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
    J Clin Oncol. 2013 Jul 10;31(20):e356 PMID: 23733772
  47. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.
    J Immunother Cancer. 2014 Dec 16;2(1):41 PMID: 25516805
  48. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
    JAMA. 2014 Nov 5;312(17 ):1744-53 PMID: 25369488
  49. Toxicities of Immunotherapy for the Practitioner.
    J Clin Oncol. 2015 Jun 20;33(18):2092-9 PMID: 25918278
  50. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    N Engl J Med. 2015 Jul 2;373(1):23-34 PMID: 26027431
  51. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    N Engl J Med. 2015 Jun 25;372(26):2509-20 PMID: 26028255
  52. Association of the autoimmune disease scleroderma with an immunologic response to cancer.
    Science. 2014 Jan 10;343 (6167):152-7 PMID: 24310608
Article Info
Journal
Rheumatic diseases clinics of North America
Abbr.
Rheum Dis Clin North Am
ISSN
1558-3163
DOI
10.1016/j.rdc.2016.09.007
Email
lcappel1@jhmi.edu
Published
2017-00-00
Epub
2016-00-22
Pages
65-78
Language
English
Region
United States
NLM ID
8708093
PMCID
PMC5127444
Subset
IM
Grants
NIAMS NIH HHS · K23 AR061439 · United States
NIAMS NIH HHS · P30 AR053503 · United States
External Links
PubMed source DOI: 10.1016/j.rdc.2016.09.007 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2